Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Oklahoma
Aulos Bioscience, Inc.
BicycleTx Limited
EMD Serono
Massachusetts General Hospital
Ocellaris Pharma, Inc.
Dana-Farber Cancer Institute
G1 Therapeutics, Inc.
VA Office of Research and Development
Queen Mary University of London